16. Plager C, Bowen JM, Fenoglio C, et al. Adjuvant immunotherapy with 
Newcastle disease virus oncolysate of M.D. Anderson Hospital (MDAH) stage III3 
malignant melanoma [abstract] . Fifth International Conference on the Adjuvant 
Therapy of Cancer, 1987. 
17. Bystryn JC, Oratz R, Harris MN, et al. Immunogenicity of polyvalent 
melanoma vaccine in humans. Cancer 61:1065, 1987. 
18. Berd D, Mastrangelo MJ. Active immunotherapy of human melanoma exploiting 
the immunopotentiating effects of cyclophosphamide. Cancer Invest 6:337, 
1988 . 
19. Slingluff CL, Vollmer R, Seigler HF . Stage II malignant melanoma: 
Presentation of a prognostic model and assessment of specific active 
immunotherapy in 1,273 patients. J Surg Oncol 39:139, 1988. 
20. Mitchell MS, Kan-Mitchell J, Kempf RA, et al. Active specific 
immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel 
adjuvant. Cancer Res 48:5883, 1988. 
21. Wallack MK, Bash J, Bartolucci A. Improvement in disease-free survival of 
melanoma patients in conjunction with serologic response in a Phase Ia/Ib 
southeastern cancer study group trial of vaccinia melanoma oncolysate. Am 
Surg 55:243, 1988. 
22. Morton DL, Nizze A, Famatiga E, et al. Clinical results of a trial of 
active specific immunotherapy with melanoma cell vaccine and immunomodulation 
in malignant melanoma [abstract]. Proc Am Assoc Cancer Res 30:383, 1989. 
23. Wiseman C, Rao S, Kennedy P, et al. Clinical response in autologous 
active specific intralymphatic immunotherapy (AASII) correlate with 
augmentation of CD4+ peripheral blood lymphocytes (PBL) [abstract] . Proc Am 
Soc Clin Oncol 1989 68:186. 
24. Livingston PO, Albino AP, Chung TJC, et al . Serological response of 
melanoma patients to vaccine prepared from VSV lysates from autologous and 
allogeneic cultured melanoma cells. Cancer 55:713, 1988. 
25. Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified 
GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad 
Sci 84:2911, 1987. 
26. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and 
IgM antibodies induced in melanoma patients. Proc Natl Acad Sci 84:2911, 
1987. 
27. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T- 
lymphocytes from normal bone marrow. Science 193:1007-1008, 1976. 
28. Rosenberg SA, Lotz MT, Mule JJ. New approaches to immunotherapy of cancer 
using interleukin-2. Ann Intern Med 108:853-864, 1988. 
29. Rosenberg SA. The development of new immunotherapies for the treatment of 
cancer using interleukin-2. Ann Surg 208:121-135, 1988. 
30. Rosenberg SA. Cancer therapy with interleukin-2: Immunologic 
manipulations can mediate the regression of cancer in humans. J Clin Oncol 
6:403-406, 1988. 
Recombinant DNA Research, Volume 18 
[361] 
